<DOC>
	<DOCNO>NCT02129088</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics ( explores body drug ) , safety tolerability esketamine , administer intranasally ( administer nose ) healthy elderly ( Cohort 1 ) healthy adult ( Cohort 2 ) participant .</brief_summary>
	<brief_title>A Pharmacokinetic , Safety Tolerability Study Esketamine Healthy Elderly Adult Participants</brief_title>
	<detailed_description>This Phase 1 , open-label ( people know identity intervention ) , single-center , single-dose study esketamine , healthy elderly ( Cohort 1 ) adult ( Cohort 2 ) participant . Cohort 1 comprise 14 healthy elderly participant ( great equal [ &gt; = ] 65 year ) least 3 participant &gt; =75 year age Cohort 2 comprise 20 healthy adult participant ( 18 55 year age , inclusive ) . The study comprise 3 phase : Screening phase , open-label Treatment phase ( consist 1 treatment period Cohort 1 2 treatment period Cohort 2 ) , Safety follow-up phase . The duration Screening phase 3 week ; duration treatment period cohort 1 3 day cohort 2 3 - 5 day ( In Treatment period 1 : 5 day first 7 participant complete additional urine fecal collection 72 hour post dose 3 day last 13 participant discharge 24 hour ; Treatment period 2 : 3 day participant ) . A washout period 5 10 day separate intranasal esketamine treatment regimen Cohort 2 . All participant Cohort 1 receive Treatment A ( , esketamine 14 milligram [ mg ] self-administered intranasal spray nostril direct supervision investigator designee ) , whereas , participant Cohort 2 receive Treatment A follow Treatment B ( , esketamine 14 mg self-administered intranasal spray follow self-administration placebo solution 5 10 minute esketamine administration nostril , direct supervision investigator designee ) fix sequence . The total esketamine dose 28 mg regimen . Blood sample collect evaluation pharmacokinetic parameter pre-dose 24 hour post-dose evaluation pharmacokinetic parameter . Participants ' safety monitor throughout study .</detailed_description>
	<criteria>Female participant must postmenopausal ( spontaneous menses least 2 year ) , surgically sterile , abstinent ( abstinence acceptable mean birth control already establish participant 's usual preferred lifestyle ) , , sexually active , practice effective method birth control ( example , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization ) entry throughout study Body mass index ( BMI ) 18 30 kilogram per square meter ( kg/m^2 ) ( inclusive ) , body weight less 50 kilogram ( kg ) Systolic blood pressure ( participant supine 5 minute ) 90 150 millimeter mercury ( mmHg ) ( inclusive ) diastolic blood pressure 90 mmHg Comfortable selfadministration intranasal medication able follow instruction provide A 12lead electrocardiogram ( ECG ) consistent normal cardiac conduction function Current significant psychiatric ( mental disorder ) disorder include limit psychotic ( person exhibit mental illness ) , bipolar , major depressive anxiety disorder Clinically significant medical illness include ( limited ) cardiac arrhythmia ( irregular heart beat ) cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia [ disorder blood ] ) , lipid abnormality , significant pulmonary ( lung ) disease , include bronchospastic respiratory disease , diabetes mellitus ( disorder decrease insulin body body 's insulin effective , result high blood sugar , increase thirst urine , many side effect ) , renal hepatic insufficiency , thyroid disease , neurologic disease , infection , hypertension vascular disorder , kidney urinary tract disturbance , sleep apnea ( breathe problem sleep ) , myasthenia gravis ( disorder cause muscle get tired quickly ) , illness Investigator considers exclude participant could interfere interpretation study result Use prescription nonprescription medication , within 14 day first schedule dose study drug Anatomical medical condition may delay delivery absorption study medication ( example . undergone facial reconstruction , structural functional abnormality nose upper airway ; obstruction mucosal lesion ( visible local abnormality tissue skin ) nostril nasal passage ; undergone sinus ( depression cavity form bend curve ) surgery previous 2 year ; sign symptoms upper respiratory infection , rhinitis , active allergy , history frequent sinus infection complication ) Has abnormal deviate nasal septum ( inner wall separate two side nose one side ) 1 follow symptom : blockage 1 nostril , nasal congestion ( especially 1sided ) , frequent nosebleed , frequent sinus infection , noisy breathe sleep , facial pain , headache , postnasal drip</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Esketamine</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Placebo</keyword>
	<keyword>Elderly</keyword>
	<keyword>Adult</keyword>
</DOC>